In Alzheimer's research, one particular protein looms large: plaque-forming amyloid-beta. Yet plaques can accumulate decades before symptoms appear, and clinical trials aimed at controlling amyloid-beta have mostly flopped so far. Scientists are using proteomics to look for alternative mechanisms and treatment strategies.